Compare CORT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | LQDA |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | 2001 | 2020 |
| Metric | CORT | LQDA |
|---|---|---|
| Price | $59.99 | $61.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $96.50 | $41.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | N/A | ★ 0.52 |
| Revenue | ★ $761,407,000.00 | $158,320,000.00 |
| Revenue This Year | $26.08 | $278.87 |
| Revenue Next Year | $26.98 | $57.13 |
| P/E Ratio | ★ N/A | $119.19 |
| Revenue Growth | 12.79 | ★ 1031.18 |
| 52 Week Low | $28.66 | $11.85 |
| 52 Week High | $91.00 | $62.30 |
| Indicator | CORT | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 74.52 | 80.46 |
| Support Level | $32.95 | $31.23 |
| Resistance Level | $90.00 | N/A |
| Average True Range (ATR) | 2.29 | 3.75 |
| MACD | 0.41 | 1.28 |
| Stochastic Oscillator | 92.09 | 96.68 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.